Wiadomości

Cocrystal Pharma Posts Wider Q3 Loss, Led By Norovirus Challenge Study Costs

NASDAQ

(RTTNews) - Cocrystal Pharma, Inc. (COCP), a clinical stage biotechnology firm, on Sunday reported a wider loss in its third quarter, driven by higher clinical trial and related expenses mainly associated with the Phase 1b norovirus challenge study of norovirus candidate CDI-988.

Przeczytaj pelny brief Veytics

Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.